Details of the Drug
General Information of Drug (ID: DM1VNEF)
Drug Name |
4-formylphenyl-O-beta-Dglucopyranoside
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Helicid; 26993-16-8; HELECIN; 4-formylphenyl b-d-glucopyranoside; 4-Formylphenyl beta-D-glucopyranoside; CHEMBL461515; 4-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde; 4-formylphenyl-O-beta-Dglucopyranoside; helicin hydrate; 4'-Formylphenyl-beta-d-glucopyranoside; Gastrodin Impurity 1; AC1OPT9G; SCHEMBL987981; CTK8F5959; MolPort-000-629-575; ZINC5234422; BDBM50245886; AKOS015960450; AC-7974; 4-formylphenyl-O-beta-D-glucopyranoside; 4-(beta-d-glucopyranosyloxy)benzaldehyde
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 284.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -0.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||